(Prudent Press Agency)---Avail Clinical Research, an Accel Research Company, located near Orlando, Florida, has recently announced the beginning of a clinical research study for people who regularly consume tobacco products such as: SNUS, snuff, chewing tobacco, dip, and other oral tobaccos.

“We are pleased to begin the screening evaluation process for our upcoming research study to test investigational treatments that may help us all understand the desire and attraction behind using these tobacco products," says Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe these clinical research trials will build significantly on the previously generated data." Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.


Avail Clinical Research is looking for regular consumers who don't intend to quit, men and women who are nineteen and older, who are also in generally good health, and who currently live in the Orlando, DeLand, and Daytona Beach region. Qualified participants will be provided with study related care, including physical examinations, laboratory services, and study medications if necessary.

Participants will be compensated up to $400 for their time and effort. For more information regarding participation in their research studies, contact Avail Clinical Research at 386-785-2400, or at www.AvailClinical.com.